(Boursier.com) — inventive rose by 2.2% this husband to 8.75 euros, while at March 31, the cash position amounted to 80.5 ME, against 95.4 ME at December 31, 2021. Net cash flows consumed by operating activities amounted to 15 ME in the 1st quarter of 2022 (7.8 ME over the same period in 2021). Research and development expenses for the 1st quarter of 2022 showed an increase of +74% compared to the 1st quarter of 2021, mainly due to the development of lanifibranor in NASH.
This significant increase in ‘R&D’ expenses is linked to the costs associated with the NATiV3 Phase III clinical study with lanifibranor in NASH. In addition, Inventiva received in January a milestone payment of 4 ME from AbbVie following the inclusion of the first patient in the Phase IIb clinical study with cedirogant in adult patients with moderate to severe psoriasis. .
Net cash flow used by investing activities in the 1st quarter of 2022 amounted to 0.1 ME in the 1st quarter of 2022 (1.1 ME in the 1st quarter of 2021). No cash flow was generated by financing activities in the 1st quarter of 2022, just like in the 1st quarter of 2021. “Rise in clinical costs, but secure cash” comments Portzamparc, which remains long, targeting a price of 27 .5 euros.
©2022 Boursier.com